If daraxonrasib is approved, doctors expect it to eventually move into earlier stages of treatment—including for patients whose cancer hasn’t spread yet or who are candidates for surgery.
“It will likely move into other settings over time,” Dr. Farrell says. “We’ll begin to see how it performs not just in advanced disease, but in patients earlier in the course of their illness.”
Researchers are also studying several other KRAS-targeted drugs, including in trials underway at Yale Cancer Center. Longer term, Dr. Farrell says, improving early detection and prevention will be just as important to reducing deaths from pancreatic cancer.
“This is just the start,” he says. “Now that we know this target can be successfully treated, it opens up the field for other drugs and new approaches.”
